- Home
- ADGM vs ZBIO Comparison
ADGM vs ZBIO Comparison
Compare ADGM & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADGM
- ZBIO
- Stock Information
- Founded
- ADGM 2011
- ZBIO 2019
- Country
- ADGM United States
- ZBIO United States
- Employees
- ADGM N/A
- ZBIO N/A
- Industry
- ADGM
- ZBIO
- Sector
- ADGM
- ZBIO
- Exchange
- ADGM NYSE
- ZBIO NYSE
- Market Cap
- ADGM 19.7M
- ZBIO 389.2M
- IPO Year
- ADGM N/A
- ZBIO 2024
- Fundamental
- Price
- ADGM $1.50
- ZBIO $12.90
- Analyst Decision
- ADGM
- ZBIO Strong Buy
- Analyst Count
- ADGM 0
- ZBIO 7
- Target Price
- ADGM N/A
- ZBIO $32.29
- AVG Volume (30 Days)
- ADGM 43.3K
- ZBIO 180.1K
- Earning Date
- ADGM 08-25-2025
- ZBIO 08-16-2025
- Dividend Yield
- ADGM N/A
- ZBIO N/A
- EPS Growth
- ADGM N/A
- ZBIO N/A
- EPS
- ADGM N/A
- ZBIO N/A
- Revenue
- ADGM $576,000.00
- ZBIO $15,000,000.00
- Revenue This Year
- ADGM N/A
- ZBIO $165.20
- Revenue Next Year
- ADGM N/A
- ZBIO $63.75
- P/E Ratio
- ADGM N/A
- ZBIO N/A
- Revenue Growth
- ADGM 116.54
- ZBIO N/A
- 52 Week Low
- ADGM $0.63
- ZBIO $5.83
- 52 Week High
- ADGM $9.34
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- ADGM N/A
- ZBIO N/A
- Support Level
- ADGM N/A
- ZBIO N/A
- Resistance Level
- ADGM N/A
- ZBIO N/A
- Average True Range (ATR)
- ADGM 0.00
- ZBIO 0.00
- MACD
- ADGM 0.00
- ZBIO 0.00
- Stochastic Oscillator
- ADGM 0.00
- ZBIO 0.00
About ADGM ADAGIO MEDICAL HOLDINGS INC
Adagio Medical Holdings Inc is an innovator in catheter ablation technologies for the treatment of cardiac arrhythmias. The company focuses on developing cryoablation technologies that create contiguous, transmural lesions to treat cardiac arrhythmias, including paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.